194 related articles for article (PubMed ID: 19887465)
1. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.
Zinzani PL; Venturini F; Stefoni V; Fina M; Pellegrini C; Derenzini E; Gandolfi L; Broccoli A; Argnani L; Quirini F; Pileri S; Baccarani M
Ann Oncol; 2010 Apr; 21(4):860-863. PubMed ID: 19887465
[TBL] [Abstract][Full Text] [Related]
2. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients.
Zinzani PL; Baliva G; Magagnoli M; Bendandi M; Modugno G; Gherlinzoni F; Orcioni GF; Ascani S; Simoni R; Pileri SA; Tura S
J Clin Oncol; 2000 Jul; 18(13):2603-6. PubMed ID: 10893292
[TBL] [Abstract][Full Text] [Related]
3. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
Zinzani PL; Magagnoli M; Bendandi M; Orcioni GF; Gherlinzoni F; Albertini P; Pileri SA; Tura S
Ann Oncol; 1998 Dec; 9(12):1351-3. PubMed ID: 9932168
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine as frontline treatment for cutaneous T-cell lymphoma: phase II study of 32 patients.
Marchi E; Alinari L; Tani M; Stefoni V; Pimpinelli N; Berti E; Pagano L; Bernengo MG; Zaja F; Rupoli S; Pileri S; Baccarani M; Zinzani PL
Cancer; 2005 Dec; 104(11):2437-41. PubMed ID: 16216001
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
Zinzani PL; Musuraca G; Tani M; Stefoni V; Marchi E; Fina M; Pellegrini C; Alinari L; Derenzini E; de Vivo A; Sabattini E; Pileri S; Baccarani M
J Clin Oncol; 2007 Sep; 25(27):4293-7. PubMed ID: 17709797
[TBL] [Abstract][Full Text] [Related]
6. Mycosis fungoides and Sezary syndrome: therapeutic approach and outcome in 113 patients.
Anadolu RY; Birol A; Sanli H; Erdem C; Türsen U
Int J Dermatol; 2005 Jul; 44(7):559-65. PubMed ID: 15985024
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
Duvic M; Talpur R; Wen S; Kurzrock R; David CL; Apisarnthanarax N
Clin Lymphoma Myeloma; 2006 Jul; 7(1):51-8. PubMed ID: 16879770
[TBL] [Abstract][Full Text] [Related]
8. [Gemcitabine Monotherapy for Advanced Mycosis Fungoides--Two Case Reports and a Literature Review].
Masuzawa M; Takasu H; Amoh Y
Gan To Kagaku Ryoho; 2015 Dec; 42(13):2451-5. PubMed ID: 26809303
[TBL] [Abstract][Full Text] [Related]
9. Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective study.
Di Raimondo C; Vaccarini S; Nunzi A; Rapisarda V; Zizzari A; Meconi F; Monopoli A; Narducci MG; Scala E; Bianchi L; Tesei C; Cantonetti M
Dermatol Ther; 2022 Jun; 35(6):e15482. PubMed ID: 35373414
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy of gemcitabine, dexamethasone, and cisplatin (GDP) for patients with relapsed or refractory peripheral T-cell lymphomas: a consortium for improving survival of lymphoma (CISL) trial.
Park BB; Kim WS; Suh C; Shin DY; Kim JA; Kim HG; Lee WS
Ann Hematol; 2015 Nov; 94(11):1845-51. PubMed ID: 26251158
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma.
Ahn HK; Kim SJ; Hwang DW; Ko YH; Tang T; Lim ST; Kim WS
Invest New Drugs; 2013 Apr; 31(2):469-72. PubMed ID: 23108598
[TBL] [Abstract][Full Text] [Related]
12. Treatment of transformed mycosis fungoides with intermittent low-dose gemcitabine.
Awar O; Duvic M
Oncology; 2007; 73(1-2):130-5. PubMed ID: 18337626
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine.
Pellegrini C; Stefoni V; Casadei B; Maglie R; Argnani L; Zinzani PL
Ann Hematol; 2014 Nov; 93(11):1853-7. PubMed ID: 24908331
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases.
Jidar K; Ingen-Housz-Oro S; Beylot-Barry M; Paul C; Chaoui D; Sigal-Grinberg M; Morel P; Dubertret L; Bachelez H
Br J Dermatol; 2009 Sep; 161(3):660-3. PubMed ID: 19438862
[TBL] [Abstract][Full Text] [Related]
15. Granulomatous mycosis fungoides with large cell transformation misdiagnosed as leprosy.
Siriphukpong S; Pattanaprichakul P; Sitthinamsuwan P; Karoopongse E
J Med Assoc Thai; 2010 Nov; 93(11):1321-6. PubMed ID: 21114213
[TBL] [Abstract][Full Text] [Related]
16. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.
Stewart JR; Desai N; Rizvi S; Zhu H; Goff HW
Eur J Dermatol; 2018 Dec; 28(6):764-774. PubMed ID: 30591425
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network.
Blazejak C; Stranzenbach R; Gosman J; Gambichler T; Wehkamp U; Stendel S; Klemke CD; Wobser M; Olk J; Nicolay JP; Weyermann M; Stadler R; Assaf C
Dermatology; 2022; 238(3):498-506. PubMed ID: 34474414
[TBL] [Abstract][Full Text] [Related]
18. Familial cutaneous mycosis fungoides: successful treatment with a combination of gemcitabine and alemtuzumab.
Weder P; Anliker M; Itin P; Bargetzi M
Dermatology; 2004; 208(3):281-3. PubMed ID: 15118391
[TBL] [Abstract][Full Text] [Related]
19. Treatment of refractory T-cell malignancies using gemcitabine.
Sallah S; Wan JY; Nguyen NP
Br J Haematol; 2001 Apr; 113(1):185-7. PubMed ID: 11328299
[TBL] [Abstract][Full Text] [Related]
20. Low-dose gemcitabine efficacious in three patients with tumor-stage mycosis fungoides.
Buhl T; Bertsch HP; Kaune KM; Mitteldorf C; Schön MP; Kretschmer L
Clin Lymphoma Myeloma; 2009 Oct; 9(5):E21-4. PubMed ID: 19858049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
